Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T12103 |
MR-L2
|
PDE | Metabolism |
MR-L2 是可逆的、非竞争性的长型异构体磷酸二酯酶 -4激活剂,可以激活代表性的 PDE4 长型异构体 (PDE4A4、PDE4B1、PDE4C3、PDE4D5)。它可抑制 PGE2- 诱导的 MDCK 细胞囊肿形成,其EC50=1.2 µM。 | |||
T64174 |
Vasopressin V2 receptor antagonist 1
|
||
Vasopressin V2 receptor antagonist 1 (Compound 4g) 是一种 vasopressin V2receptor (V2R) 拮抗剂 (Ki: 3.8 nM)。Vasopressin V2 receptor antagonist 1 可以用于研究常染色体显性多囊肾病 (ADPKD)。 | |||
T73163 | CDK7-IN-20 | ||
CDK7-IN-20 是一种有效的、选择性的、不可逆的 CDK7(CDK) 抑制剂,IC50值为 4 nM。CDK7-IN-20 对 CDK7的选择性超过 CDK1、CDK2、CDK3、CDK5、CDK6、CDK9 和 CDK12的 206 倍以上。CDK7-IN-20 具有用于常染色体显性多囊肾病 (ADPKD) 研究的潜力。 | |||
T39712 |
RGLS4326
RG4326,RGLS4326 |
||
RGLS4326 (RG4326) is a short oligonucleotide inhibitor of microRNA-17 (miR-17), with a pioneering role in its class. This compound, with a research focus on autosomal dominant polycystic kidney disease (ADPKD), effectively suppresses the activity of miR-17 in HeLa cells, displaying an EC50 value of 28.3 nM. | |||
T61362 |
CDK5-IN-3
|
||
CDK5-IN-3 (compound 11) is a highly potent and selective inhibitor of CDK5, demonstrating significant inhibition with IC50 values of 0.6 nM and 18 nM for CDK5/p25 and CDK2/CycA, respectively. This compound holds promise for further investigation in the context of autosomal dominant polycystic kidney disease (ADPKD) research [1]. | |||
T72076 |
H2-Gamendazole
|
HSP | Cytoskeletal Signaling; Metabolism |
H2-Gamendazole 是一种抑制精子发生和癌症治疗的新型化合物,可作为热休克蛋白和/或延伸因子1 α的抑制剂,是 Hsp90调节剂。 |